Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Incyte Corporation (ICY.F)

Compare
66.78
-3.56
(-5.06%)
As of 8:01:25 AM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
4,241,217
4,241,217
3,695,649
3,394,635
2,986,267
Cost of Revenue
312,100
312,100
255,000
207,000
150,991
Gross Profit
3,929,117
3,929,117
3,440,649
3,187,635
2,835,276
Operating Expense
3,827,823
3,827,823
2,790,939
2,596,009
2,234,758
Operating Income
101,294
101,294
649,710
591,626
600,518
Net Non Operating Interest Income Expense
126,430
126,430
155,863
37,785
8,739
Other Income Expense
88,831
88,831
28,625
-100,258
-38,813
Pretax Income
316,630
316,630
834,215
529,116
570,444
Tax Provision
284,015
284,015
236,616
188,456
-378,137
Net Income Common Stockholders
32,615
32,615
597,599
340,660
948,581
Diluted NI Available to Com Stockholders
32,615
32,615
597,599
340,660
948,581
Basic EPS
0.10
0.16
2.67
1.53
4.30
Diluted EPS
0.09
0.15
2.65
1.52
4.27
Basic Average Shares
214,879.25
207,110
223,628
222,004
220,428
Diluted Average Shares
215,433.25
210,530
225,928
223,958
222,074
Total Operating Income as Reported
61,366
61,366
620,525
579,440
585,777
Total Expenses
4,139,923
4,139,923
3,045,939
2,803,009
2,385,749
Net Income from Continuing & Discontinued Operation
32,615
32,615
597,599
340,660
948,581
Normalized Income
-27,442.38
-27,442.38
587,080.24
404,891.92
976,914.49
Interest Income
128,710
128,710
158,414
40,451
10,647
Interest Expense
2,280
2,280
2,551
2,666
1,908
Net Interest Income
126,430
126,430
155,863
37,785
8,739
EBIT
318,910
318,910
836,766
531,782
572,352
EBITDA
408,158
408,158
919,426
599,637
630,196
Reconciled Cost of Revenue
312,100
312,100
255,000
207,000
150,991
Reconciled Depreciation
89,248
89,248
82,660
67,855
57,844
Net Income from Continuing Operation Net Minority Interest
32,615
32,615
597,599
340,660
948,581
Total Unusual Items Excluding Goodwill
76,022
76,022
14,691
-99,739
-38,813
Total Unusual Items
76,022
76,022
14,691
-99,739
-38,813
Normalized EBITDA
332,136
332,136
904,735
699,376
669,009
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
15,964.62
15,964.62
4,172.24
-35,507.08
-10,479.51
12/31/2021 - 1/3/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KK3A.BE Cytokinetics Inc
41.40
+0.98%
 
222110.KQ PanGen Biotech Inc.
5,240.00
+4.59%
 
FTD.SG Financière de Tubize SA
151.40
+2.85%
 
NKB2.F TG Therapeutics, Inc.
32.37
-3.20%
 
NRIX Nurix Therapeutics, Inc.
13.76
-3.03%
 
VCEL Vericel Corporation
48.83
-1.37%
 
GNPX Genprex, Inc.
0.3353
-3.65%
 
PTCT PTC Therapeutics, Inc.
51.08
-3.38%
 
CYTK Cytokinetics, Incorporated
42.91
+0.05%
 
ATYR aTyr Pharma, Inc.
2.9300
-11.21%